Actinium Pharmaceuticals, Inc.
ATNM · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $49,913 | $43,674 | $50,226 | $39,307 |
| - Cash | $53,391 | $59,928 | $65,325 | $72,904 |
| + Debt | $1,143 | $1,290 | $1,433 | $1,573 |
| Enterprise Value | -$2,335 | -$14,964 | -$13,666 | -$32,024 |
| Revenue | $90 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$116 | -$204 | -$205 | -$204 |
| % Margin | -128.9% | – | – | – |
| EBITDA | -$4,925 | -$6,674 | -$15,733 | -$6,448 |
| % Margin | -5,472.2% | – | – | – |
| Net Income | -$5,131 | -$6,878 | -$15,938 | -$6,652 |
| % Margin | -5,701.1% | – | – | – |
| EPS Diluted | -0.16 | -0.22 | -0.51 | -0.21 |
| % Growth | 27.3% | 56.9% | -142.9% | – |
| Operating Cash Flow | -$6,325 | -$5,392 | -$7,574 | -$5,751 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$6,325 | -$5,392 | -$7,574 | -$5,751 |